The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema in 1206 obese or overweight adults aged 18 years and older with type 2 diabetes.
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo Nordisk said in a release.The headline results ...
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.
Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The ...
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The ...
At 68 weeks, 89.7% of adults with obesity and type 2 diabetes lost 5% or more body weight with CagriSema. Detailed results from the REDEFINE 1 and REDEFINE 2 trials will be presented later in 2025.
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, compared to placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback